QCI Asset Management’s Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible PPHMP Stock Holding History

QCI Asset Management’s Portfolio PPHMP Stock Details PPHMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-80	Closed	-$2K	–	614
2018 Q1	$2K	Hold	80	–	–	﹤0.01%	561
2017 Q4	$2K	Buy	+80	New	+$1.91K	﹤0.01%	575

QCI Asset Management's PPHMP Position: Q2 2018 in Review

QCI Asset Management sold out of Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible (PPHMP) in Q2 2018, closing a stake of 80 shares — an estimated $2K sold.

QCI Asset Management first reported a position in PPHMP in Q4 2017 and held it in 2 quarters. The position peaked at $2K in Q1 2018. 0 funds tracked by Wall St. Rank hold PPHMP as of Q2 2018.

QCI Asset Management reported no remaining Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible position as of Q2 2018 after selling out during the quarter.
QCI Asset Management sold 80 Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible shares in Q2 2018, an estimated $2K.
QCI Asset Management first reported a position in Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible in Q4 2017 and held it in 2 quarters.
QCI Asset Management's Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible position peaked at $2K in Q1 2018.
0 funds tracked by Wall St. Rank held Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible as of Q2 2018.

Based on QCI Asset Management's 13F filing for Q2 2018, filed 6 Aug 2018.